Relmada Therapeutics Issues 100K Stock Options to New Director

Rhea-AI Filing Summary

Relmada Therapeutics, Inc. (RLMD) filed a Form 4 disclosing a new equity award to director John Glasspool. On 06/26/2025, Glasspool received 100,000 non-qualified stock options with an exercise price of $0.67 per share. The options vest in 16 equal quarterly installments starting 09/26/2025 and expire on 06/26/2035. No common shares were bought or sold; the only reported transaction is the option grant, leaving Glasspool with 100,000 derivative securities held directly. The filing indicates normal onboarding compensation and modest potential dilution relative to RLMD’s outstanding share count (not provided in the document). Investors should view the grant as routine governance practice that aligns the new director’s incentives with long-term shareholder value without any immediate cash outlay or ownership change.

Insights

Corporate Governance Analyst

TL;DR: Routine director option grant; aligns incentives, minor dilution, neutral overall impact.

The Form 4 shows RLMD issued 100,000 options to incoming director John Glasspool at a $0.67 strike. A 10-year term and four-year quarterly vesting are typical for small-cap biotech governance structures, rewarding long-term board service and performance alignment. Because no shares were sold and the exercise price equals future cash inflow, the transaction is non-dilutive today and only mildly dilutive if exercised. Without further context on total shares outstanding, the grant appears immaterial to capitalization. There are no red flags such as accelerated vesting, below-market pricing, or insider sales. Consequently, I classify the filing as governance-routine with negligible immediate financial impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GLASSPOOL JOHN

(Last) (First) (Middle)

C/O RELMADA THERAPEUTICS, INC.

2222 PONCE DE LEON BLVD, 3RD FLOOR

(Street)

CORAL GABLES, FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RELMADA THERAPEUTICS, INC. [ RLMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.67	06/26/2025		A		100,000		09/26/2025(1)	06/26/2035	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The options vest in 16 equal quarterly installments commencing on September 26, 2025.

	/s/ John Glasspool	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.